Literature DB >> 31673381

Mobile phone text-messaging interventions aimed to prevent cardiovascular diseases (Text2PreventCVD): systematic review and individual patient data meta-analysis.

Sheikh Mohammed Shariful Islam1,2,3, Andrew J Farmer4, Kirsten Bobrow4, Ralph Maddison1, Robyn Whittaker5, Leila Anne Pfaeffli Dale5, Andreas Lechner6, Scott Lear7, Zubin Eapen8, Louis Wilhelmus Niessen9, Karla Santo2,3, Sandrine Stepien2, Julie Redfern2,3, Anthony Rodgers10, Clara K Chow2,3.   

Abstract

Background: A variety of small mobile phone text-messaging interventions have indicated improvement in risk factors for cardiovascular disease (CVD). Yet the extent of this improvement and whether it impacts multiple risk factors together is uncertain. We aimed to conduct a systematic review and individual patient data (IPD) meta-analysis to investigate the effects of text-messaging interventions for CVD prevention.
Methods: Electronic databases were searched to identify trials investigating a text-messaging intervention focusing on CVD prevention with the potential to modify at least two CVD risk factors in adults. The main outcome was blood pressure (BP). We conducted standard and IPD meta-analysis on pooled data. We accounted for clustering of patients within studies and the primary analysis used random-effects models. Sensitivity and subgroup analyses were performed.
Results: Nine trials were included in the systematic review involving 3779 participants and 5 (n=2612) contributed data to the IPD meta-analysis. Standard meta-analysis showed that the weighted mean differences are as follows: systolic blood pressure (SBP), -4.13 mm Hg (95% CI -11.07 to 2.81, p<0.0001); diastolic blood pressure (DBP), -1.11 mm Hg (-1.91 to -0.31, p=0.002); and body mass index (BMI), -0.32 (-0.49 to -0.16, p=0.000). In the IPD meta-analysis, the mean difference are as follows: SBP, -1.3 mm Hg (-5.4 to 2.7, p=0.5236); DBP, -0.8 mm Hg (-2.5 to 1.0, p=0.3912); and BMI, -0.2 (-0.8 to 0.4, p=0.5200) in the random-effects model. The impact on other risk factors is described, but there were insufficient data to conduct meta-analyses.
Conclusion: Mobile phone text-messaging interventions have modest impacts on BP and BMI. Simultaneous but small impacts on multiple risk factors are likely to be clinically relevant and improve outcome, but there are currently insufficient data in pooled analyses to examine the extent to which simultaneous reduction in multiple risk factors occurs. PROSPERO registration number: CRD42016033236. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiovascular diseases; cardiovascular risk factors; diabetes; mHealth; mobile phones; short message service

Year:  2019        PMID: 31673381      PMCID: PMC6802999          DOI: 10.1136/openhrt-2019-001017

Source DB:  PubMed          Journal:  Open Heart        ISSN: 2053-3624


A variety of small mobile phone text-messaging interventions have indicated improvement in risk factors for cardiovascular disease (CVD). This is the first individual patient data meta-analysis showing the impact of text messaging on secondary prevention of CVD. Text messaging is acceptable, generalisable and scalable and has modest impacts on multiple CVD risk factors with public health significance.

Introduction

Globally, deaths due to cardiovascular disease (CVD) have steadily increased over the last four decades,1 with ischaemic heart diseases remaining as the single largest cause of death.2 A large body of evidence has demonstrated that common and modifiable risk factors, including high blood pressure (BP), smoking, high cholesterol, obesity and physical inactivity, contribute substantially to the risk of CVD and premature death.3–8 However, identifying low-cost, scalable and effective strategies to target all of these to prevent CVD and recurrent CVD events remains a major challenge. In recent years, mobile health (mHealth) programmes have emerged as a strategy to support chronic health conditions. Much of the fervour around mHealth has been because of the potential seen to reduce socioeconomic disparity and to deliver a scalable low-cost intervention to a wide population and thus alleviate the burden of CVD.9 Two systematic reviews on mHealth interventions for secondary prevention of CVD reported that mHealth offers potential for improving CVD secondary prevention.10 11 The 2018 review7 included 9 (n=3637) studies using text messaging, and the 2016 study8 included 28 studies (n=3820) using mHealth technologies (including text messaging, mobile apps and internet); neither of the reviews performed meta-analysis. The majority of studies showed the effectiveness of mHealth and text messaging in improving behaviours, patient satisfaction and clinical outcomes in patients with CVD. Text messaging and apps showed the highest user adherence and satisfaction compared with internet or continuous monitoring. The 2018 review concluded that text messaging might be a useful tool for secondary prevention of CVD, but conclusions were largely based on qualitative assessment of studies, and the 2016 review concluded that mobile phone features such as text messaging and apps have a strong potential to positively impact the secondary prevention of CVD. They suggested further research was needed to apply rigorous research designs with theory-based interventions, to measure economic benefits, process evaluation and adverse effects of the intervention, and were unable to address the frequency and content of text messaging and long-term impacts of the intervention on clinical outcomes and end points. The global reach and ubiquity of mHealth interventions suggest they may be useful, but despite almost a decade of research, the evidence base remains limited. In this context, we performed a systematic review and meta-analysis of randomised controlled trials (RCTs) of text-messaging interventions used for the prevention of CVD risk factors to generate robust evidence and to identify researchers active in this field. We established the Text2PreventCVD Trial Collaborators Group, a global network of researchers working on mHealth interventions in CVD prevention and management, with the goals of collaboration to facilitate the next generation of trials. In the current paper, the Text2PreventCVD Collaboration aimed to quantify the extent of improvement in cardiovascular risk factors with mobile phone text-messaging interventions using systematic review and individual participant data (IPD) meta-analysis. Studies included needed to involve interventions that had the potential to impact on at least two measures of cardiovascular risk factors. The primary outcome designated for these analyses was systolic blood pressure (SBP) and the secondary outcomes included diastolic blood pressure (DBP) and body mass index (BMI).

Methods

We performed a systematic review and IPD meta-analysis and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and the Cochrane Collaboration reporting items for systematic reviews and meta-analysis guidelines.12 This review is registered in the International Prospective Register of Systematic Reviews. The study protocol has been published previously.13

Search strategy

We searched MEDLINE, Embase, PsycINFO (Ovid) and the Cochrane Central Register of Controlled Trials for reports published from 1 January 1990 to 1 July 2016 to identify RCTs of text-messaging interventions used for the prevention of CVD risk factors. The following Medical Subject Headings search terms were used: (1) intervention (text messaging, text messages, short message service (SMS), text message mobile phone, cellular phone, texting, SMS); (2) CVD (heart disease, coronary disease, BP, hypertension, lipids, cholesterol, cardiovascular risk factors, myocardial infarction, vascular, diabetes and obesity) and (3) study design (RCT). We also searched for ongoing, recently completed and unpublished clinical trials meeting the inclusion criteria described earlier from different trial registers and reference lists of selected studies, and reviewed grey literature for any other relevant studies. Consultation and contacts with experts in the field were made to help identify relevant studies.

Study eligibility

Full details of the methods used have been reported previously.13 In brief, studies were eligible if they were RCTs of a text-messaging intervention focused on CVD prevention (primary or secondary) with at least two behaviour change strategies, for example, physical activity and diet or BP lowering, smoking and cholesterol lowering14; study duration was at least 6 months and 70% completed the follow-up of participants; study participants were adults, the sample size was larger than 30 people, and the control group received standard care. Reports published in any language were considered.

Study selection and data extraction

Two researchers (SMSI and KS) independently screened titles and abstracts to identify studies meeting the inclusion criteria described previously. One researcher (SMSI) extracted and tabulated all relevant data in a predefined data extraction sheet and a second researcher (KS) checked it for accuracy. Extracted data included patient’s baseline characteristics; the type and duration of the intervention; changes in SBP and DBP, BMI, weight and lipids; and any possible adverse outcome reported. Disagreement was resolved by consensus or in consultation with a third reviewer (CKC). Corresponding authors of the selected studies were invited to join the Text2PreventCVD Collaboration and to contribute data to the IPD meta-analysis.

Outcomes

The primary outcome was the difference between intervention and control groups in SBP at 6 months. However, as two studies15 16 did not have complete SBP data at 6 months’ follow-up, we performed the analysis based on end of follow-up data. We also sought to examine other measures of cardiovascular risk, including low-density lipoprotein (LDL) cholesterol, smoking, diet, quality of life and physical activity. However, due to insufficient data availability, we were only able to conduct meta-analysis to analyse diastolic BP and BMI as secondary outcomes at the end of the follow-up period.

Assessment of study quality

Study quality was assessed using the Cochrane collaboration risk of bias assessment tool,17 based on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias.

Statistical analysis

Analyses were conducted in accordance with contemporary recommendations for IPD meta-analyses.18–21 Primary and secondary outcome analyses were performed on the combined dataset using preferred one-stage IPD meta-analyses (ie, individual patient data (IPD) were pooled and then models run on the combined dataset).20 22 The primary analyses consisted of a linear mixed model with the end-of-trial value as the outcome, the baseline value and the treatment arm as random effects, and a random trial intercept and random trial-by-treatment interaction. An interim meta-analysis (standard meta-analysis) of the systematic review was performed using both fixed and random-effects models to compare the results with the IPD meta-analysis. Sensitivity analyses included two-stage approaches using both random and fixed-effects meta-analyses, analysis of 6-month follow-up values as the outcome and excluding data from the heart exercise and remote technologies (HEART) study, which measured BP in the context of participants doing exercise. Subgroup analyses were performed using the one-stage IPD and fitting a subgroup and subgroup by treatment interaction fixed effect into the model so heterogeneity between subgroup categories (education, age and gender) could be assessed. All data analyses were carried out using STATA V.12 and SAS V.9.2.

Results

Study characteristics

Out of a total of 1210 identified citations, nine trials consisting of 3779 participants met the inclusion criteria of our systematic search (figure 1). We contacted all nine study groups and five agreed to contribute data to the IPD meta-analysis described further. Characteristics of the nine trials are shown in table 1. The median sample size was 236 (range 123–1372) and the median intervention period was 6 months (range 6–24 months). The mean age of the participants was 54.1±5.5 years and 37.5% were women. The gender spread across the studies was broad from one study of 100% men23 to one with <30%.15 The trials included participants with a range of levels of absolute cardiovascular risk from primary prevention to secondary prevention populations. Of the nine trials included, one trial included ‘normal’ participants not on drug therapy,23 with the others including patient populations selected on the basis of having a cardiovascular risk factor or CVD; for example, two studies included participants with high BP,15 16 three with coronary heart diseases,24–26 two with diabetes,27 28 one included only working men with no diabetes23 and one participant taking medication for either BP or lipid lowering.29 Five studies recruited participants from hospital settings,16 24–26 28 two from primary healthcare settings,15 29 one from a hospital emergency department27 and one in an industrial area work setting.23 The duration of the text-messaging intervention was 6 months for seven studies,24–29 12 months for one15 and 24 months for another.23
Figure 1

Study selection process. CENTRAL, Cochrane Central Register of Controlled Trials. CVD, cardiovascular disease; IPD, individual patient data; SMS, short message service.

Table 1

Characteristics of the study using text message intervention for CVD prevention

Author,year(trial)Sample sizeDurationAge (years)*Male (%)Intervention versus controlParticipant characteristicsSetting,countryPrimary outcomeSecondary outcome
Arora et al,2014 (TExT-MED)27 1286 months50.7±10.236Text messages versus no text messagePatients with poorly controlled diabetes (HbA1c>8%)Emergency department,LA CountyHospital, University of Southern California, USAChange in HbA1cMedication adherence, self-efficacy, performance of self-care tasks, QoL, diabetes-specific knowledge, ED use and patient satisfaction.
Bobrow et al,2016 (StAR)†15 42 137212 months54.3±11.528Usual care versus informational SMS versus interactive SMSPatients treated for high BPSingle primary care centre in Cape Town, South AfricaChange in mean SBP from baseline to 12 monthsProportion of BP<140/90, medication adherence by PDC and self-report, QoL (EQ5D), clinic attendance and retention, satisfaction with clinic services and care, hospital admissions and basic hypertension knowledge
Chow et al,2015 (TEXT ME)†24 41 7106 months57.9±9.181.5Usual care versus text messaging+usual carePatients with documented CHDA large metropolitan tertiary referral public hospital in Sydney, AustraliaChange in plasmaLDL cholesterol at 6 monthsChange in SBP, BMI, WC, total cholesterol, HR, smoking status, QoL (SF-12), medication adherence, physical activity, proportion achieving modifiable risk factors, PHQ-9 and nutritional status
Islam et al,2015 (MPID)†28 43 2366 months48.1±9.745.8Routine care versus SMS+routine carePatients with type 2 diabetes on oral therapyTertiary hospital outpatient department, Dhaka, BangladeshMean changes in HbA1c at 6 monthsMedication adherence, QoL (EQ5D), physical activity, PHQ-9, BP, WC, BMI and diet
Kiselev et al, 201216 19912 months50±1155Active ambulatory care management supported by SMS versus traditional ambulatory care managementPatients with arterial hypertensionAmbulatory department of the Saratov Research Institute of Cardiology,Saratov, Russia.BP levelsBMI and smoking rates
Maddison et al,2015 (HEART)†26 31 1716 months60.2±9.381Mobile phone text messages and internet intervention plus usual care, or usual care aloneAdults with a diagnosis of IHD, able to perform exercise and who had access to the internet.Two metropolitan hospitals in Auckland, New ZealandChange in maximal oxygen uptake at 6 monthsPhysical activity (IPAQ), SBP, weight, waist:hip ratio, self-efficacy, QoL (SF-36 and EQ5D) and cost-effectiveness
Pfaeffli Dale et al, 2015 (Text4Heart)†25 44 1236 months59.5±11.181.3Centre-based CR (usual care) versus text messages and a supporting website+usual careAdults diagnosed with CHDTwo large metropolitan hospitals in Auckland, NZProportion of participants adhering to healthy behaviours at 6 monthsBP, lipid profile, weight, BMI, waist:hip ratio, self-efficacy, depression and medication adherence
Ramachandran et al,201323 53724 months46±4.7100Mobile phone messaging intervention or standard careWorking Indian men aged 35–55 years with BMI of ≥23 kg/m2 with no diabetes or major illnessPublic and private-sector industrial units in southeast IndiaIncidence of type 2 diabetesBMI, WC, SBP, DBP, lipid profile, total dietary energy intake and physical activity score
Wald et al,201429 3036 months60 (54–68)53.8Text group versus no text groupPatients taking BP and/or lipid-lowering medications7 Primary care practices in London, UKMedication use at 6 months, exceeding 80% of the prescribed regimenProportion of patients continuing their medications, taking >80% of their prescribed regimen, BP, total cholesterol and LDL

*Age in years (mean±SD/median (IQR)).

†Studies included in the individual patient data meta-analysis.

BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CR, cardiac rehabilitation; CVD, cardiovascular disease; DBP, diastolic blood pressure; ED, emergency department; EQ5D, EuroQol Group 5-Dimension Self-report Questionnaire; HbA1c, haemoglobin A1c; IHD, ischaemic heart disease; LDL, low-density lipoprotein; PDC, proportion of days of medication covered; PHQ-9, Patient Health Questionnaire 9; QoL, quality of life; SBP, systolic blood pressure; SF-12, short form 12; SF-36, short form 36; SMS, short message service; StAR, SMS Text-message adherence suppoRt tria; TEXT ME, Effect of Lifestyle-Focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial; TExT-MED, Trial to examine text message-based mHealth in emergency department patients with diabetes; WC, waist circumference.

Study selection process. CENTRAL, Cochrane Central Register of Controlled Trials. CVD, cardiovascular disease; IPD, individual patient data; SMS, short message service. Characteristics of the study using text message intervention for CVD prevention *Age in years (mean±SD/median (IQR)). †Studies included in the individual patient data meta-analysis. BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CR, cardiac rehabilitation; CVD, cardiovascular disease; DBP, diastolic blood pressure; ED, emergency department; EQ5D, EuroQol Group 5-Dimension Self-report Questionnaire; HbA1c, haemoglobin A1c; IHD, ischaemic heart disease; LDL, low-density lipoprotein; PDC, proportion of days of medication covered; PHQ-9, Patient Health Questionnaire 9; QoL, quality of life; SBP, systolic blood pressure; SF-12, short form 12; SF-36, short form 36; SMS, short message service; StAR, SMS Text-message adherence suppoRt tria; TEXT ME, Effect of Lifestyle-Focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial; TExT-MED, Trial to examine text message-based mHealth in emergency department patients with diabetes; WC, waist circumference.

Text message intervention characteristics

There was considerable variation in the characteristics of the individual text-message interventions (see online supplementary table S1). Five studies provided text messages as a stand-alone intervention. Four studies provided additional support to participants in the form of telephone support16 29 and via secure website.25 26 Message frequency varied from one message per week up to two messages per day. Four studies sent text messages at a fixed predetermined frequency.24 27–29 Most studies used unidirectional text messaging and three used interactive text messaging.15 25 29 Six studies used personalised or semipersonalised text messages, while three studies used generalised messages.16 27 28 Message content was based on clinical guidelines (five studies), expert opinion (two studies) and feedback from formative qualitative work (three studies). The number of behaviour change strategies used ranged from 2 to 17. Seven studies reported patient feedback on the text messaging.16 23–29

Standard meta-analysis of the intervention efficacy

Of the 3779 participants, 295 did not have complete data and were excluded from the analysis. In the pooled analysis of 3348 patients, using a random-effects model, text message intervention significantly reduced SBP at the end of follow-up (weighted mean difference −4.13 mm Hg (95% CI −11.07 to −2.81, p=<0.0001) (figure 2). There was high heterogeneity (I2 97.3%) across the clinical trials due to one study with a large effect size.16 The weighted mean difference in DBP was −1.11 mm Hg (95% CI −1.91 to −0.31, p=0.002, I2 77.2%) and BMI was −0.32 (95% CI −0.49 to −0.158, <0.0001, I2 91.5%).
Figure 2

Standard meta-analysis at end follow-up on systolic blood pressure results (random-effects model). MPID, mobile phone intervention for diabetes; WMD, weighted mean difference.

Standard meta-analysis at end follow-up on systolic blood pressure results (random-effects model). MPID, mobile phone intervention for diabetes; WMD, weighted mean difference.

IPD meta-analysis of the intervention efficacy

The IPD meta-analysis involved five studies with 1976 participants from Australia, Bangladesh, New Zealand and South Africa (table 2). The mean difference in SBP at the end of the follow-up period was −1.3 mm Hg (95% CI −5.4 to 2.7, p=0.5236, I2 89.0%) in the random-effects model. The mean differences in DBP and BMI were −0.8 mm Hg (95% CI −2.5 to 1.0, p=0.3912, I2 77.2%) and −0.2 mm Hg (95% CI −0.8 to 0.4, p=0.5200, I2 91.5%), respectively, at the end of the follow-up using the random-effects model (table 3).
Table 2

Trials included in the individual patient data meta-analysis with outcomes by trial at the end of follow-up*

TrialLocationParticipantsOutcomenInterventionControlMean difference (95% CI)P value for the difference
Systolic blood pressure (mm Hg) at end of follow-up
 HEART31 New ZealandIHDNumber of observations1527478
Analysis of covariance135.7 (132.7 to 138.6)131.1 (128.3 to 134.0)4.6 (0.5 to 8.7)0.0289
 MPID28 BangladeshDiabetesNumber of observations236118118
Analysis of covariance127.1 (124.8 to 129.4)126.7 (124.4 to 129.0)0.4 (−2.8 to 3.7)0.7968
 StAR15 South AfricaHypertensionNumber of observations802406396
Analysis of covariance133.2 (131.7 to 134.8)135.4 (133.8 to 136.9)−2.1 (−4.3 to 0.1)0.0599
 Text4Heart25 New ZealandCHDNumber of observations1145658
Analysis of covariance135.5 (130.9 to 140.1)135.4 (130.8 to 139.9)0.1 (−6.4 to 6.6)0.9800
 TEXT ME24 AustraliaCHDNumber of observations672329343
Analysis of covariance128.2 (126.7 to 129.8)135.8 (134.3 to 137.3)−7.6 (−9.8 to −5.4)<0.0001
Diastolic blood pressure (mm Hg) at the end of follow-up
 HEART31 New ZealandIHDNumber of observations1527478
Analysis of covariance79.3 (77.4 to 81.3)77.7 (75.8 to 79.6)1.6 (−1.1 to 4.4)0.2483
 MPID28 BangladeshDiabetesNumber of observations236118118
Analysis of covariance79.1 (77.9 to 80.4)78.2 (76.9 to 79.4)1.0 (−0.8 to 2.8)0.2844
 StAR15 South AfricaHypertensionNumber of observations802406396
Analysis of covariance82.9 (81.9 to 84.0)84.0 (83.0 to 85.1)−1.1 (−2.6 to 0.4)0.1497
 Text4Heart25 New ZealandCHDNumber of observations1145658
Analysis of covariance79.4 (76.8 to 82.0)79.6 (77.1 to 82.1)−0.2 (−3.8 to 3.4)0.9019
 TEXT ME24 AustraliaCHDNumber of observations673329344
Analysis of covariance80.5 (79.6 to 81.5)83.6 (82.7 to 84.5)−3.1 (−4.4 to −1.7)<0.0001
BMI (kg/m2) at the end of follow-up
 HEART31 New ZealandIHDNumber of observations1527478
Analysis of covariance28.7 (28.4 to 28.9)28.5 (28.2 to 28.7)0.2 (−0.1 to 0.5)0.2569
 MPID28 BangladeshDiabetesNumber of observations1639073
Analysis of covariance26.5 (25.9 to 27.1)26.0 (25.4 to 26.7)0.4 (−0.5 to 1.3)0.3425
 StAR15 South AfricaHypertensionNumber of observations795401394
Analysis of covariance33.5 (33.3 to 33.7)33.7 (33.5 to 33.9)−0.1 (−0.4 to 0.2)0.3732
 Text4Heart25 New ZealandCHDNumber of observations1135558
Analysis of covariance29.1 (28.8 to 29.4)29.2 (28.9 to 29.5)−0.1 (−0.6 to 0.3)0.6015
 TEXT ME24 AustraliaCHDNumber of observations684335349
Analysis of covariance29.0 (28.8 to 29.3)30.3 (30.1 to 30.5)−1.3 (−1.6 to −0.9)<0.0001

Note: All randomised patients with both visits assessed at baseline and at the end of follow-up have been included in this analysis.

End of follow-up corresponds to month 12 for StAR study and month 6 for other studies.

Primary analysis—non-adjusted model: analysis of covariance including randomised treatment and baseline value.

n is the total number of observations used (available) for the analysis at month 6 using baseline value as covariate.

CHD, coronary heart disease; IHD, ischaemic heart disease; MPID, mobile phone intervention for diabetes; StAR, Mobile Phone Text Messages to Support Treatment Adherence in Adults With High Blood Pressure (SMS-Text Adherence Support); TEXT ME, Effect of Lifestyle-Focused text messaging on risk factor modification in patients with coronary heart disease; TExT-MED, Trial to examine text message-based mHealth in emergency department patients with diabetes.

Table 3

Individual patient data meta-analysis at the end of follow-up*

OutcomeModelInterventionControlMean difference(95% CI)P value for the difference
SBPRandom-effects model (1a)132.1 (128.7 to 135.5)133.4 (130.0 to 136.8)−1.3 (−5.4 to 2.7)0.5236
Fixed-effects model (2)131.3 (130.2 to 132.4)134.3 (133.2 to 135.4)−3.1 (−4.4 to −1.7)<0.0001
DBPRandom-effects model (1a)80.9 (79.4 to 82.4)81.7 (80.2 to 83.2)−0.8 (−2.5 to 1.0)0.3912
Fixed-effects model (2)80.6 (79.8 to 81.3)81.9 (81.2 to 82.6)−1.3 (−2.2 to −0.5)0.0018
BMIRandom-effects model (1b)30.6 (30.2 to 31.1)30.8 (30.4 to 31.3)−0.2 (−0.8 to 0.4)0.5200
Fixed-effects model (2)30.5 (30.3 to 30.7)31.0 (30.8 to 31.1)−0.5 (−0.7 to −0.3)<0.0001

Note: All randomised patients with both visits assessed at baseline and at month 6 have been included in this analysis.

Primary analysis—analysis of covariance, including randomised treatment and baseline value as fixed effect: model 1: (a) includes trial random effect and random treatment by trial interaction, (b) includes trial fixed effect and random treatment by trial interaction when model 1a estimates trial random effect to zero; model 2: only fixed effects, including trial effect; model 3: sensitivity analysis pooling the estimates from the five trials using a standard meta-analysis checking for data heterogeneity between trials.

*For the StAR study, 12 month data was used for follow-up. For all other studies, 6 month data was used for follow-up.

BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.

Trials included in the individual patient data meta-analysis with outcomes by trial at the end of follow-up* Note: All randomised patients with both visits assessed at baseline and at the end of follow-up have been included in this analysis. End of follow-up corresponds to month 12 for StAR study and month 6 for other studies. Primary analysis—non-adjusted model: analysis of covariance including randomised treatment and baseline value. n is the total number of observations used (available) for the analysis at month 6 using baseline value as covariate. CHD, coronary heart disease; IHD, ischaemic heart disease; MPID, mobile phone intervention for diabetes; StAR, Mobile Phone Text Messages to Support Treatment Adherence in Adults With High Blood Pressure (SMS-Text Adherence Support); TEXT ME, Effect of Lifestyle-Focused text messaging on risk factor modification in patients with coronary heart disease; TExT-MED, Trial to examine text message-based mHealth in emergency department patients with diabetes. Individual patient data meta-analysis at the end of follow-up* Note: All randomised patients with both visits assessed at baseline and at month 6 have been included in this analysis. Primary analysis—analysis of covariance, including randomised treatment and baseline value as fixed effect: model 1: (a) includes trial random effect and random treatment by trial interaction, (b) includes trial fixed effect and random treatment by trial interaction when model 1a estimates trial random effect to zero; model 2: only fixed effects, including trial effect; model 3: sensitivity analysis pooling the estimates from the five trials using a standard meta-analysis checking for data heterogeneity between trials. *For the StAR study, 12 month data was used for follow-up. For all other studies, 6 month data was used for follow-up. BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.

Other CVD risk factors

Three studies25 27 28 included in the standard meta-analysis reported effects of text messaging on medication adherence using Morisky’s eight-item medication adherence scale (MMAS-8).30 These studies showed improvement in the MMAS-8 score to a varying degree 1.1 (95% CI 0.1 to 2.1), −0.11 (95% CI −0.49 to 0.26) and 0.58 (95% CI 0.19 to 0.97). Three studies measured changes in LDL cholesterol, but data were presented in reports for only two studies −0.11 mg/dL (95% CI −0.49 to 0.26, p=0.04)24 and −0.25 mg/dL (95% CI −0.49 to 0.01, p=0.053).25 Two studies reported changes in glycated haemoglobin with a mean difference of −0.45% (p=0.230)27 and −0.64% (−0.95 to −0.33).28 With respect to whether interventions impacted on multiple cardiovascular risk factors, four studies15 23 24 28 showed statistically significant reductions in two or more cardiovascular risk factors, while two studies27 31reported improvements (not statistically significant) in two or more cardiovascular risk factors at the end of the study (see online supplementary table S5). One study reported concurrent reductions in LDL cholesterol, BP, BMI, physical activity and smoking, with 28.9% achieving at least four guideline levels of cardiovascular risk factors in the intervention group, compared with 10.3% in the control group and 4.7% achieving all five guideline levels in the intervention group, compared with 1.8% in the control group.24

Sensitivity analysis

A sensitivity analysis was conducted in which data from the HEART trial26 were excluded, mainly because BP was measured in the context of cardiopulmonary exercise testing. As a result, reductions were found for SBP −3.7 mm Hg (95% CI −5.1 to −2.3), DBP −1.6 mm Hg (95% CI −2.5 to −0.7) and BMI −0.5 (95% CI −0.7 to −0.3) (see online supplementary table S2).

Effects stratified by subgroup analysis

To further assess the impact of text messages, we performed an analysis based on participant characteristics. The moderators assessed were education (<12 years vs ≥12 years), age (<60 years vs ≥60 year) and gender (male vs female). There was no significant variation in the effectiveness of text message intervention by strata (see online supplementary table S3).

Study quality

We assessed the study quality as per Cochrane guidelines12 (see online supplementary table S4). All studies described a randomisation sequence generation technique that was at low risk of bias except one that had an unclear risk of bias.16 Three studies did not report allocation concealment and were categorised as unclear allocation concealment.16 23 27 Blinding of study participants was not possible due to the nature of intervention for any of the studies. Blinding of outcome assessments was not clearly described in four studies.16 25 27 29 Six studies were reported to have low incomplete outcome data,15 23–27 29 one with unclear outcome data28 and one with high incomplete outcome data.16 All studies scored low in selective reporting and other bias, while only one study had unclear other bias.16 Overall, 7 (78 %) studies were thought to be of high quality with a maximum of one unclear assessment.15 23–26 28 29 Publication bias could not be assessed as the number of trials was few.

Text message acceptability

Participant feedback on text-message acceptability was reported in seven studies16 23–28 (see online supplementary table S2). Most studies reported moderate to high levels of satisfaction with the text-messaging programme. Participants acknowledged text-message support as a useful and expressed desire to programme continuation. In one study,28 32 participants were willing to pay a small fee to receive the text-messaging programme. In one study, a small fraction (3%) of the participants felt that the messages were disturbing.23

Discussion

The main findings of this paper is that mobile phone text-messaging interventions have modest impacts on objective measures of cardiovascular risk factors of BP and BMI in analyses of pooled data using standard and IPD meta-analyses. Modest impacts on cardiovascular risk factors could have clinical and/or public health significance if they could impact on multiple risk factors simultaneously and/or do this at a very low cost, but the current data are not conclusive on these points. The pooled data are from a number of different regions, and the high acceptability of texting interventions reported by most studies in our review suggests generalisability of findings and potential for widespread implementation, but there is still relatively few large-scale or multicentre evaluations. Efficient, simultaneous risk factor reduction is important in the prevention of CVD as risk reduction is additive across single risk factors; for example, BP lowering plus lipid lowering is more effective at reducing risk than either alone. The reasons that the data are still inconclusive are likely because of the small number of individual participants in trials, the heterogeneity of the study population (including primary and secondary prevention populations), the heterogeneity of the interventions and the likely small individual impact of the interventions themselves. Mobile phone text messaging might be a low-cost intervention, but data on cost-effectiveness are still limited. One of the studies included had a published cost-effectiveness study that modelled implementation of the text-message intervention to a target population of 50 000 patients with coronary heart disease; the intervention was estimated to lead to 563 fewer myocardial infarctions, 361 fewer strokes and 1143 additional quality adjusted life years, and was associated with an overall saving of $10.56 million for the health system over the patients’ lifetimes.33 There have been some previous systematic reviews in mHealth interventions for CVD secondary prevention. One recent systematic review of mobile phone interventions for secondary prevention of CVD reported that text messaging was effective in improving clinical outcomes better than smartphone-based interventions.11 The study discussed that incorporating principles of behavioural change may help promote and sustain healthy lifestyle behaviours in patients with CVD, resulting in better outcomes.11 Another systematic review of mobile phone text messaging for improving secondary prevention in CVD suggested that text messaging might be beneficial for secondary prevention of CVD but failed to draw reliable conclusions.10 A 2017 systematic review identified six studies using text messaging for hypertension management but did not perform meta-analysis due to variation in the studies.34 The study concluded that text messaging had strong potential for innovation in hypertension management, especially in minority groups and those with low access to healthcare services. All these systematic reviews suggested that text messaging might have a role in secondary prevention of CVD but could not quantify effectiveness due to a lack of meta-analysis. Our study is therefore unique as it used IPD as well as meta-analysis. The main mechanism by which texting intervention appear to work is via behavioural change. All trials included in our review incorporated two or more behaviour change theories. Behaviour change interventions and techniques, including motivational interviewing,35 increasing patient motivation and self-efficacy,36 goal setting combined with self-monitoring of behaviour,37 supporting medical adherence and multimodal behavioural interventions, have been highlighted as effective in various CVD prevention programmes.38 39 Text messaging offers confidential and unobtrusive support, which is an advantage over other interventions.

Strengths and limitations

The primary limitation of this meta-analysis was the differences in participants’ characteristics, risk factor measurements and primary outcomes of interest across studies. A potential limitation is the small number of trials and a highly significant study included in the meta-analysis,16 potential publication bias and influence of heterogeneity is possible. Of the nine trials included in the standard meta-analysis, we were only able to obtain full datasets from five trials. Also, we calculated the effect estimate from available data from published studies, and it is thus possible that bias can be introduced from differential loss to follow-up. Therefore, the results of this IPD meta-analysis cannot be generalised across different populations and should be interpreted with caution. Finally, the meta-analysis is not a mechanistic study; thus, we cannot determine whether the benefit associated with the use of text messaging was attributable to BP lowering or to other mechanisms. The primary strength of this meta-analysis was its systematic search to identify potential studies and the inclusion of only RCTs, which are less subject to bias and confounding than observational studies. The IPD analysis approach used in this study has advantages over a meta-analysis because the outcomes can be matched between studies and all studies are then analysed in the same prespecified statistical model. The use of data from many studies with different inclusion criteria should make the findings more generalisable, and the robustness of the main conclusions to subsidiary methods of analysis further supports the conclusion drawn.

Future research

There are still a number of unanswered questions that we were unable to adequately address, for example, whether different characteristics of the texting interventions influenced outcomes (ie, number of behaviour change techniques used, unidirectional vs bidirectional, high vs low frequency, personalised vs non-personalised). How can effects be maintained into the longer term and how are interventions best scaled up to populations? Future studies should address these questions, as well as the potential of these interventions in varied socioeconomic groups, age groups and cultures. Variations in effectiveness of behavioural interventions have been shown by gender.37 40 In addition, substantial variability exists with regard to the definitions of outcome measures for the different cardiovascular risk factors across studies. A standardised method for measuring the different outcomes in CVD prevention is warranted to improve comparability of outcome measures across studies for a more rigorous and reliable evaluation of the effectiveness of mHealth interventions for CVD.

Conclusion

Mobile phone text-messaging interventions have modest impacts on objective measures of BP and BMI. Evidence is suggestive, but inconclusive, that texting is acceptable, generalisable and scalable, and their modest impacts on cardiovascular risk factors may apply to multiple cardiovascular risk factors and hence make this a mHealth solution with public health significance.
  42 in total

1.  Adiposity as compared with physical activity in predicting mortality among women.

Authors:  Frank B Hu; Walter C Willett; Tricia Li; Meir J Stampfer; Graham A Colditz; JoAnn E Manson
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

Review 2.  Use of Short Messaging Service for Hypertension Management: A Systematic Review.

Authors:  Grecia Vargas; Maan Isabella Cajita; Erin Whitehouse; Hae-Ra Han
Journal:  J Cardiovasc Nurs       Date:  2017 May/Jun       Impact factor: 2.083

3.  Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women.

Authors:  Timothy R Wessel; Christopher B Arant; Marian B Olson; B Delia Johnson; Steven E Reis; Barry L Sharaf; Leslee J Shaw; Eileen Handberg; George Sopko; Sheryl F Kelsey; Carl J Pepine; Noel Bairey Merz
Journal:  JAMA       Date:  2004-09-08       Impact factor: 56.272

Review 4.  mHealth in Cardiovascular Health Care.

Authors:  Clara K Chow; Nilshan Ariyarathna; Sheikh Mohammed Shariful Islam; Aravinda Thiagalingam; Julie Redfern
Journal:  Heart Lung Circ       Date:  2016-05-11       Impact factor: 2.975

5.  Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation.

Authors:  Gary J Balady; Mark A Williams; Philip A Ades; Vera Bittner; Patricia Comoss; JoAnne M Foody; Barry Franklin; Bonnie Sanderson; Douglas Southard
Journal:  Circulation       Date:  2007-05-18       Impact factor: 29.690

6.  Effectiveness of mobile phone messaging in prevention of type 2 diabetes by lifestyle modification in men in India: a prospective, parallel-group, randomised controlled trial.

Authors:  Ambady Ramachandran; Chamukuttan Snehalatha; Jagannathan Ram; Sundaram Selvam; Mary Simon; Arun Nanditha; Ananth Samith Shetty; Ian F Godsland; Nish Chaturvedi; Azeem Majeed; Nick Oliver; Christofer Toumazou; K George Alberti; Desmond G Johnston
Journal:  Lancet Diabetes Endocrinol       Date:  2013-09-11       Impact factor: 32.069

Review 7.  Mobile Phone Interventions for the Secondary Prevention of Cardiovascular Disease.

Authors:  Linda G Park; Alexis Beatty; Zoey Stafford; Mary A Whooley
Journal:  Prog Cardiovasc Dis       Date:  2016-03-18       Impact factor: 8.194

8.  Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321

9.  Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321

10.  Individual participant data meta-analysis for a binary outcome: one-stage or two-stage?

Authors:  Thomas P A Debray; Karel G M Moons; Ghada Mohammed Abdallah Abo-Zaid; Hendrik Koffijberg; Richard David Riley
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

View more
  20 in total

1.  Digital health approaches for cardiovascular diseases prevention and management: lessons from preliminary studies.

Authors:  Sheikh Mohammed Shariful Islam; Ralph Maddison
Journal:  Mhealth       Date:  2021-07-20

2.  2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society.

Authors:  Niraj Varma; Iwona Cygankiewicz; Mintu P Turakhia; Hein Heidbuchel; Yu-Feng Hu; Lin Yee Chen; Jean-Philippe Couderc; Edmond M Cronin; Jerry D Estep; Lars Grieten; Deirdre A Lane; Reena Mehra; Alex Page; Rod Passman; Jonathan P Piccini; Ewa Piotrowicz; Ryszard Piotrowicz; Pyotr G Platonov; Antonio Luiz Ribeiro; Robert E Rich; Andrea M Russo; David Slotwiner; Jonathan S Steinberg; Emma Svennberg
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-02-12

3.  2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society.

Authors:  Niraj Varma; Iwona Cygankiewicz; Mintu P Turakhia; Hein Heidbuchel; Yufeng Hu; Lin Yee Chen; Jean-Philippe Couderc; Edmond M Cronin; Jerry D Estep; Lars Grieten; Deirdre A Lane; Reena Mehra; Alex Page; Rod Passman; Jonathan P Piccini; Ewa Piotrowicz; Ryszard Piotrowicz; Pyotr G Platonov; Antonio Luiz Ribeiro; Robert E Rich; Andrea M Russo; David Slotwiner; Jonathan S Steinberg; Emma Svennberg
Journal:  Cardiovasc Digit Health J       Date:  2021-01-29

4.  Machine learning models for prediction of co-occurrence of diabetes and cardiovascular diseases: a retrospective cohort study.

Authors:  Ahmad Shaker Abdalrada; Jemal Abawajy; Tahsien Al-Quraishi; Sheikh Mohammed Shariful Islam
Journal:  J Diabetes Metab Disord       Date:  2022-01-12

Review 5.  Smartphone Apps for Diabetes Medication Adherence: Systematic Review.

Authors:  Sheikh Mohammed Shariful Islam; Vinaytosh Mishra; Muhammad Umer Siddiqui; Jeban Chandir Moses; Sasan Adibi; Lemai Nguyen; Nilmini Wickramasinghe
Journal:  JMIR Diabetes       Date:  2022-06-21

6.  Consensus on Recommended Functions of a Smart Home System to Improve Self-Management Behaviors in People With Heart Failure: A Modified Delphi Approach.

Authors:  Sheikh Mohammed Shariful Islam; Rebecca Nourse; Riaz Uddin; Jonathan C Rawstorn; Ralph Maddison
Journal:  Front Cardiovasc Med       Date:  2022-06-29

7.  A digital health intervention for cardiovascular disease management in primary care (CONNECT) randomized controlled trial.

Authors:  Julie Redfern; Genevieve Coorey; John Mulley; Anish Scaria; Lis Neubeck; Nashid Hafiz; Chris Pitt; Kristie Weir; Joanna Forbes; Sharon Parker; Fiona Bampi; Alison Coenen; Gemma Enright; Annette Wong; Theresa Nguyen; Mark Harris; Nick Zwar; Clara K Chow; Anthony Rodgers; Emma Heeley; Katie Panaretto; Annie Lau; Noel Hayman; Tim Usherwood; David Peiris
Journal:  NPJ Digit Med       Date:  2020-09-10

8.  An Intervention to Improve Medication Adherence in People With Heart Disease (Text4HeartII): Randomized Controlled Trial.

Authors:  Ralph Maddison; Yannan Jiang; Ralph Stewart; Tony Scott; Andrew Kerr; Robyn Whittaker; Jocelyn Benatar; Anna Rolleston; Paul Estabrooks; Leila Dale
Journal:  JMIR Mhealth Uhealth       Date:  2021-06-09       Impact factor: 4.773

Review 9.  Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension.

Authors:  Bin Zhou; Pablo Perel; George A Mensah; Majid Ezzati
Journal:  Nat Rev Cardiol       Date:  2021-05-28       Impact factor: 32.419

Review 10.  Ethnicity and Metabolic Syndrome: Implications for Assessment, Management and Prevention.

Authors:  Scott A Lear; Danijela Gasevic
Journal:  Nutrients       Date:  2019-12-19       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.